Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADITYA H GAUR

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1124021258
CMS profile
322624
Location
MEMPHIS, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,948.91

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,600.00 1
Travel and Lodging $715.60 3
Food and Beverage $633.31 8

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $3,585.62 8
Gilead Sciences, Inc. $363.29 4

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADITYA H GAUR

NPI 1124021258 · CMS profile ID 322624

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

MEMPHIS, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124021258?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADITYA H GAUR, NPI 1124021258, CMS profile ID 322624. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124021258?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ADITYA H GAUR, NPI 1124021258, CMS profile ID 322624. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124021258?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ADITYA H GAUR, NPI 1124021258, CMS profile ID 322624, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1124021258?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $3,948.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $162.0410/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133835236 CMS
ViiV Healthcare Company $43.8608/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112724880 CMS
ViiV Healthcare Company $46.1108/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112761622 CMS
ViiV Healthcare Company $80.7908/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112803707 CMS
ViiV Healthcare Company $99.2608/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112815305 CMS
ViiV Healthcare Company $275.9408/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112794452 CMS
Gilead Sciences, Inc. $21.0008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133835234 CMS
Gilead Sciences, Inc. $50.0008/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133835232 CMS
ViiV Healthcare Company $408.6407/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112752184 CMS
ViiV Healthcare Company $31.0207/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112789836 CMS
ViiV Healthcare Company $2,600.0006/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112810897 CMS
Gilead Sciences, Inc. $130.2506/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133835230 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $3,220.00 1
PY2023 $105.33 1
PY2024 $3,948.91 12
PY2025 $1,745.30 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $30,992.64 25
PY2024 Principal investigator $109,202.34 31
PY2023 Principal investigator $49,580.00 24
PY2022 Principal investigator $325,385.33 16
PY2021 Principal investigator $628,189.72 22
PY2020 Principal investigator $146,539.82 24
PY2019 Principal investigator $78,758.09 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $898.00 12/22/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 803516503
Principal investigator 1 Gilead Sciences, Inc. $2,142.00 12/22/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 803526121
Principal investigator 1 Gilead Sciences, Inc. $10,332.00 12/22/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS 5423 and GS 2872 in Combination with Capsid Inhibitor Lenacapavir (GS 6207) in Virologically Suppressed Adults with HIV-1 Infection No dispute reported 06/30/2026 803526123
Principal investigator 1 Gilead Sciences, Inc. $898.00 09/22/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 803516501
Principal investigator 1 Gilead Sciences, Inc. $2,767.00 09/22/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 803526119
Principal investigator 1 Gilead Sciences, Inc. $3,600.00 09/01/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 803516499
Principal investigator 1 Gilead Sciences, Inc. $21,572.00 08/30/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People at least 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 803526117
Principal investigator 1 Gilead Sciences, Inc. $17,079.00 08/16/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS 5423 and GS 2872 in Combination with Capsid Inhibitor Lenacapavir (GS 6207) in Virologically Suppressed Adults with HIV-1 Infection No dispute reported 06/30/2026 803526115
Principal investigator 1 Gilead Sciences, Inc. $1,690.00 08/09/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 803516497
Principal investigator 1 Gilead Sciences, Inc. $28.17 07/26/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 803516495
Principal investigator 1 Gilead Sciences, Inc. $3,640.00 07/26/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 803526113
Principal investigator 1 ViiV Healthcare Company $87,974.00 07/03/2021 Non-covered Recipient Entity
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
PHASE I/II STUDY OF THE SAFETY, ACCEPTABILITY, TOLERABILITY, AND PHARM No dispute reported 06/30/2026 803290589
Principal investigator 1 Gilead Sciences, Inc. $1,376.00 06/23/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 803516491
Principal investigator 1 Gilead Sciences, Inc. $9,300.00 06/23/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children No dispute reported 06/30/2026 803516493
Principal investigator 1 ViiV Healthcare Company $229,124.18 06/01/2021 Non-covered Recipient Entity
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
PHASE I/II STUDY OF THE SAFETY, ACCEPTABILITY, TOLERABILITY, AND PHARM No dispute reported 06/30/2026 803289853
Principal investigator 1 Gilead Sciences, Inc. $2,498.00 05/19/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 803526111
Principal investigator 1 Gilead Sciences, Inc. $681.00 04/26/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 803526109
Principal investigator 1 Gilead Sciences, Inc. $830.00 03/17/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 803516489
Principal investigator 1 ViiV Healthcare Company $84,417.50 03/01/2021 Non-covered Recipient Entity
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
PHASE I/II STUDY OF THE SAFETY, ACCEPTABILITY, TOLERABILITY, AND PHARM No dispute reported 06/30/2026 803289831
Principal investigator 1 Gilead Sciences, Inc. $1,297.00 02/17/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 803526107
Principal investigator 1 ViiV Healthcare Company $144,909.87 02/01/2021 Non-covered Recipient Entity
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
PHASE I/II STUDY OF THE SAFETY, ACCEPTABILITY, TOLERABILITY, AND PHARM No dispute reported 06/30/2026 803289833
Principal investigator 1 Gilead Sciences, Inc. $1,136.00 01/20/2021 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV No dispute reported 06/30/2026 803526105